# biote Corp.: overview

BTMD · Nasdaq · CIK 1819253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/btmd.md) · [Financials](/companies/btmd/financials.md) · [Filings](/companies/btmd/filings.md) · [Insiders](/companies/btmd/insiders.md)

Latest reported revenue: [$44.2m](/filings/0001193125-26-340364.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-340364).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [51.4](/filings/0001193125-25-272294.md) | [49.8 d](/filings/0001193125-26-106099.md) | [49.0](/filings/0001193125-26-216780.md) | [48.9](/filings/0001193125-26-340364.md) | [48.0](/filings/0001193125-25-272294.md) | [46.4 d](/filings/0001193125-26-106099.md) | [44.9](/filings/0001193125-26-216780.md) | [44.2](/filings/0001193125-26-340364.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [23.7%](/filings/0001193125-25-272294.md) | [5.6% d](/filings/0001193125-26-106099.md) | [19.8%](/filings/0001193125-26-216780.md) | [22.0%](/filings/0001193125-26-340364.md) | [17.2%](/filings/0001193125-25-272294.md) | [14.7% d](/filings/0001193125-26-106099.md) | [7.0%](/filings/0001193125-26-216780.md) | [(7.9%)](/filings/0001193125-26-340364.md) |
| Net margin | % | [20.8%](/filings/0001193125-25-272294.md) | [7.4% d](/filings/0001193125-26-106099.md) | [28.0%](/filings/0001193125-26-216780.md) | [6.5%](/filings/0001193125-26-340364.md) | [17.1%](/filings/0001193125-25-272294.md) | [4.2% d](/filings/0001193125-26-106099.md) | [5.1%](/filings/0001193125-26-216780.md) | [(14.8%)](/filings/0001193125-26-340364.md) |
| Diluted EPS | $ per share | [0.33](/filings/0001193125-25-272294.md) | not reported | [0.37](/filings/0001193125-26-216780.md) | [0.10](/filings/0001193125-26-340364.md) | [0.22](/filings/0001193125-25-272294.md) | not reported | [0.06](/filings/0001193125-26-216780.md) | [(0.23)](/filings/0001193125-26-340364.md) |
| Free cash flow | $m | [14.0 d](/filings/0001193125-25-272294.md) | [10.7 d](/filings/0001193125-26-106099.md) | [4.8](/filings/0001193125-26-216780.md) | [5.3 d](/filings/0001193125-26-340364.md) | [13.6 d](/filings/0001193125-25-272294.md) | [6.5 d](/filings/0001193125-26-106099.md) | [3.5](/filings/0001193125-26-216780.md) | [(3.7) d](/filings/0001193125-26-340364.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [139](/filings/0000950170-23-010664.md) | [165](/filings/0000950170-24-032101.md) | [185](/filings/0000950170-25-039394.md) | [197](/filings/0001193125-26-106099.md) | [192](/filings/0001193125-26-106099.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [24.8%](/filings/0000950170-23-010664.md) | [(36.8%)](/filings/0000950170-24-032101.md) | [15.5%](/filings/0000950170-25-039394.md) | [16.0%](/filings/0001193125-26-106099.md) | [18.5%](/filings/0001193125-26-106099.md) |
| Net margin | % | [8.0%](/filings/0001193125-22-097864.md) | [(0.6%)](/filings/0000950170-24-032101.md) | [1.8%](/filings/0000950170-25-039394.md) | [1.6%](/filings/0001193125-26-106099.md) | [14.1%](/filings/0001193125-26-106099.md) |
| Diluted EPS | $ per share | not reported | [(0.12)](/filings/0000950170-24-032101.md) | [0.13](/filings/0000950170-25-039394.md) | [0.09](/filings/0001193125-26-106099.md) | [0.74](/filings/0001193125-26-106099.md) |
| Free cash flow | $m | [32.3](/filings/0000950170-23-010664.md) | [(9.5)](/filings/0000950170-24-032101.md) | [26.5](/filings/0000950170-25-039394.md) | [38.8](/filings/0001193125-26-106099.md) | [30.2](/filings/0001193125-26-106099.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/btmd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [325 CAPITAL LLC](/funds/1873893.md) | 2026-06-30 | $8.6m | 4,548,127 |  | Unchanged |
| [Bandera Partners LLC](/funds/1399386.md) | 2026-06-30 | $3.9m | 2,065,482 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.1m | 1,102,753 |  | Reduced −11,102 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $824.2k | 436,088 |  | New +436,088 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $816.1k | 431,962 |  | Reduced −111,532 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $691.6k | 365,945 |  | Reduced −1,373,299 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $569.5k | 301,310 |  | New +301,310 |
| [RICE HALL JAMES & ASSOCIATES, LLC](/funds/1230765.md) | 2026-06-30 | $496.8k | 262,842 |  | Added +12,823 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $492.6k | 260,488 |  | Reduced −355,174 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $478.8k | 253,313 |  | New +253,313 |

## Recent filings

[All 407 filings](/companies/btmd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 16:30 ET | [10-Q](/filings/0001193125-26-340364.md) | Quarterly report, period 2026-06-30 | 0001193125-26-340364 |
| 2026-08-05 | 16:20 ET | [8-K](/filings/0001193125-26-335200.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335200 |
| 2026-06-17 | 16:05 ET | [8-K/A](/filings/0001193125-26-274137.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-274137 |
| 2026-06-02 | 17:17 ET | [8-K](/filings/0001193125-26-253858.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-253858 |
| 2026-05-18 | 16:30 ET | [8-K](/filings/0001193125-26-229013.md) | 5.07 Shareholder vote results | 0001193125-26-229013 |
| 2026-05-11 | 16:11 ET | [10-Q](/filings/0001193125-26-216780.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216780 |
| 2026-05-06 | 16:10 ET | [8-K](/filings/0001193125-26-208965.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208965 |
| 2026-04-03 | 16:10 ET | [8-K](/filings/0001193125-26-142147.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-142147 |
| 2026-04-02 | 16:10 ET | [DEF 14A](/filings/0001193125-26-140096.md) | Proxy statement, period 2026-05-12 | 0001193125-26-140096 |
| 2026-03-13 | 16:04 ET | [10-K](/filings/0001193125-26-106099.md) | Annual report, period 2025-12-31 | 0001193125-26-106099 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-106099.md), filed Mar 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/42cf7eea-d09a-4164-b891-09c088c6db64)

## About the filer

- CIK: 1819253
- Tickers: BTMD
- Exchange: Nasdaq
- SIC code: 2833 Medicinal Chemicals & Botanical Products
- State of incorporation: not reported
- Filer category: Accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.